יומירה 40 מ"ג

מדינה: ישראל

שפה: עברית

מקור: Ministry of Health

מרכיב פעיל:

ADALIMUMAB 40 MG / 0.8 ML

זמין מ:

ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL

קוד ATC:

L04AA17

טופס פרצבטיות:

SOLUTION FOR INJECTION

הרכב:

PEN

מסלול נתינה (של תרופות):

S.C

תוצרת:

ABBVIE LTD, UK

קבוצה תרפויטית:

ADALIMUMAB

סממני תרפויטית:

* Rheumatoid arthritis: Humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray adn to impove physical function when given in combination with methotrexate. * Crohn's disease : Humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.Humira is indicated for reducing signs and symptoms and inducing clinical r

תאריך אישור:

2009-07-01